178 related articles for article (PubMed ID: 11555010)
1. Use of various combinations of free, complexed and total prostate-specific antigen levels as predictors of the pathologic stage of prostate cancer.
Okegawa T; Noda H; Ohta M; Kato M; Nutahara K; Higashihara E
Int J Urol; 2001 Aug; 8(8):438-43. PubMed ID: 11555010
[TBL] [Abstract][Full Text] [Related]
2. Volume indexes of total, free, and complexed prostate-specific antigen enhance prediction of extraprostatic disease extension in men with nonpalpable prostate cancer.
Naya Y; Fritsche HA; Cheli CD; Stamey TA; Bartsch G; Brawer MK; Childs S; Taneja SS; Lepor H; Partin AW; Sokoll LJ; Chan DW; Babaian RJ
Urology; 2003 Dec; 62(6):1058-62. PubMed ID: 14665355
[TBL] [Abstract][Full Text] [Related]
3. Comparisons of the various combinations of free, complexed, and total prostate-specific antigen for the detection of prostate cancer.
Okegawa T; Noda H; Nutahara K; Higashihara E
Eur Urol; 2000 Oct; 38(4):380-7. PubMed ID: 11025374
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of three molecular forms of prostate-specific antigen ratios in patients with prostate adenocarcinoma.
Okegawa T; Kato M; Nutahara K; Higashihara E
Urology; 2001 May; 57(5):936-42. PubMed ID: 11337298
[TBL] [Abstract][Full Text] [Related]
5. Predictors of prostate cancer on repeat prostatic biopsy in men with serum total prostate-specific antigen between 4.1 and 10 ng/mL.
Okegawa T; Kinjo M; Ohta M; Miura I; Horie S; Nutahara K; Higashihara E
Int J Urol; 2003 Apr; 10(4):201-6. PubMed ID: 12657099
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the clinical validity of free prostate-specific antigen, alpha-1 antichymotrypsin-bound prostate-specific antigen and complexed prostate-specific antigen in prostate cancer diagnosis.
Lein M; Jung K; Elgeti U; Petras T; Stephan C; Brux B; Sinha P; Winkelmann B; Schnorr D; Loening S
Eur Urol; 2001 Jan; 39(1):57-64. PubMed ID: 11173940
[TBL] [Abstract][Full Text] [Related]
7. Complexed prostate-specific antigen, complexed prostate-specific antigen density of total and transition zone, complexed/total prostate-specific antigen ratio, free-to-total prostate-specific antigen ratio, density of total and transition zone prostate-specific antigen: results of the prospective multicenter European trial.
Djavan B; Remzi M; Zlotta AR; Ravery V; Hammerer P; Reissigl A; Dobronski P; Kaisary A; Marberger M
Urology; 2002 Oct; 60(4 Suppl 1):4-9. PubMed ID: 12384156
[TBL] [Abstract][Full Text] [Related]
8. Complexed prostate-specific antigen as a staging tool: results based on a multicenter prospective evaluation of complexed prostate-specific antigen in cancer diagnosis.
Taneja SS; Hsu EI; Cheli CD; Walden P; Bartsch G; Horninger W; Babaian RJ; Fritsche HA; Childs S; Stamey TA; Sokoll LJ; Chan DW; Brawer MK; Partin AW; Lepor H
Urology; 2002 Oct; 60(4 Suppl 1):10-7. PubMed ID: 12384157
[TBL] [Abstract][Full Text] [Related]
9. Comparison of two investigative assays for the complexed prostate-specific antigen in total prostate-specific antigen between 4.1 and 10.0 ng/mL.
Okegawa T; Noda H; Nutahara K; Higashihara E
Urology; 2000 May; 55(5):700-4. PubMed ID: 10792084
[TBL] [Abstract][Full Text] [Related]
10. Human glandular kallikrein as a tool to improve discrimination of poorly differentiated and non-organ-confined prostate cancer compared with prostate-specific antigen.
Recker F; Kwiatkowski MK; Piironen T; Pettersson K; Huber A; Lümmen G; Tscholl R
Urology; 2000 Apr; 55(4):481-5. PubMed ID: 10736487
[TBL] [Abstract][Full Text] [Related]
11. Ratio of free or complexed prostate-specific antigen (PSA) to total PSA: which ratio improves differentiation between benign prostatic hyperplasia and prostate cancer?
Jung K; Elgeti U; Lein M; Brux B; Sinha P; Rudolph B; Hauptmann S; Schnorr D; Loening SA
Clin Chem; 2000 Jan; 46(1):55-62. PubMed ID: 10620572
[TBL] [Abstract][Full Text] [Related]
12. Comparison of serum prostate specific membrane antigen, prostate specific antigen, and free prostate specific antigen levels in radical prostatectomy patients.
Douglas TH; Morgan TO; McLeod DG; Moul JW; Murphy GP; Barren R; Sesterhenn IA; Mostofi FK
Cancer; 1997 Jul; 80(1):107-14. PubMed ID: 9210715
[TBL] [Abstract][Full Text] [Related]
13. Comparison of several combinations of free, complexed, and total PSA in the diagnosis of prostate cancer in patients with urologic symptoms.
Filella X; Truan D; Alcover J; Quintó L; Molina R; Luque P; Coca F; Ballesta AM
Urology; 2004 Jun; 63(6):1100-3; discussion 1103-4. PubMed ID: 15183958
[TBL] [Abstract][Full Text] [Related]
14. Human glandular kallikrein 2 levels in serum for discrimination of pathologically organ-confined from locally-advanced prostate cancer in total PSA-levels below 10 ng/ml.
Haese A; Graefen M; Steuber T; Becker C; Pettersson K; Piironen T; Noldus J; Huland H; Lilja H
Prostate; 2001 Oct; 49(2):101-9. PubMed ID: 11582588
[TBL] [Abstract][Full Text] [Related]
15. The role of the complexed-to-total prostate-specific antigen ratio in predicting the final pathological stage of clinically localized prostate cancer.
Martínez M; Navarro S; Medina P; Villavicencio H; Rioja L; Solsona E; Estellés A; Aznar J; Jiménez-Cruz JF; España F
Eur Urol; 2003 Jun; 43(6):609-14. PubMed ID: 12767360
[TBL] [Abstract][Full Text] [Related]
16. [The application of complexed PSA and its relative indexes in the diagnosis of prostate cancer].
Chen ZH; Zhao J; Wu JM; Xiao CG
Zhonghua Nan Ke Xue; 2003 Feb; 9(1):36-9. PubMed ID: 12680329
[TBL] [Abstract][Full Text] [Related]
17. The significance of the free-to-complexed prostate-specific antigen (PSA) ratio in prostate cancer detection in patients with a PSA level of 4.1-10.0 ng/mL.
Okegawa T; Kinjo M; Watanabe K; Noda H; Kato M; Miyata A; Murata A; Yoshii M; Nutahara K; Higashihara E
BJU Int; 2000 Apr; 85(6):708-14. PubMed ID: 10759671
[TBL] [Abstract][Full Text] [Related]
18. Comparative evaluation of various prostate specific antigen ratios for the early detection of prostate cancer.
Ozdal OL; Aprikian AG; Bégin LR; Behlouli H; Tanguay S
BJU Int; 2004 May; 93(7):970-4; discussion 974. PubMed ID: 15142145
[TBL] [Abstract][Full Text] [Related]
19. Complexed prostate-specific antigen as a staging tool for prostate cancer: a prospective study in 420 men.
Sokoll LJ; Mangold LA; Partin AW; Epstein JI; Bruzek DJ; Dunn W; Mohr P; Wallerson G; Chan DW
Urology; 2002 Oct; 60(4 Suppl 1):18-23. PubMed ID: 12384158
[TBL] [Abstract][Full Text] [Related]
20. Complexed prostate-specific antigen for early detection of prostate cancer in men with serum prostate-specific antigen levels of 2 to 4 nanograms per milliliter.
Horninger W; Cheli CD; Babaian RJ; Fritsche HA; Lepor H; Taneja SS; Childs S; Stamey TA; Sokoll LJ; Chan DW; Brawer MK; Partin AW; Bartsch G
Urology; 2002 Oct; 60(4 Suppl 1):31-5. PubMed ID: 12384160
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]